OCGN · Transaction Nov 8, 2022 · Filed Dec 12, 2022 · $1,001 to $15,000
NASDAQ NMS - GLOBAL MARKET · OCGN
-0.94% · -$0.0100 · Vol 4.2M
After hours · updated 18:42:10 ET
Ocugen Inc
Biotechnology
$1.05
Follow $OCGN
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $OCGN by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredMon Sep 21 · session closed · Markets closed · resumes Tue 9:30 ET · OCGN
MethodologyOCGN
Ocugen Inc
Mon Sep 21 · session closed · Markets closed · resumes Tue 9:30 ET
Lower range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
33/ 100
Veridion Score
Lower range · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6 of 6 factors measured · Mon Sep 21 · session closed · Markets closed · resumes Tue 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is OCGN moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Ocugen Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Listed since
2014
Employees
116
Country
US
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$1.05
Day high
$1.08
Day low
$1.02
Previous close
$1.06
52W high
$2.48
-57.66% from high
52W low
$0.9935
4% of range
Market cap
$359.5M
EPS
$-0.2600
Beta
1.53
Shares out
339.1M
Volume
4.2M
0.66× rel vol
Avg volume
6.3M
VWAP
$1.04
Price history computed in-house
1W
-0.94%
1M
-24.46%
3M
-23.91%
1Y
-21.64%
YTD
-22.22%
SMA 50 $1.28 · below
SMA 200 $1.51 · below
52W position 4%
OCGN overview
Related filings and maps
Public disclosures
Congress activity in OCGN
Official filing ↗
Chris JacobsSell
Ocugen, Inc. · Transaction Nov 8, 2022 · Filed Dec 12, 2022 · $1,001 to $15,000
OCGN · Transaction Jun 16, 2022 · Filed Jul 28, 2022 · $15,001 to $50,000
Federal contracts
OCGN contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for OCGN in this window.
Lobbying spend
OCGN lobbying filings, year to date.
Registered lobbying filings matched to Ocugen Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for OCGN in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for OCGN.
Options
Sovereign unlock shows live options positioning for OCGN.